(UroToday.com) At the Society of Urologic Oncology (SUO) virtual annual meeting, Dr. James Wysock gave an update on the use of imaging in primary prostate cancer diagnosis. The PROMIS trial demonstrated that the use of multi-parametric MRI (mpMRI) improved sensitivity by 93% compared to transrectal ultrasound (TRUS), which has a sensitivity of only 48%1.
The PRECISION trial, MRI-Targeted vs Standard Biopsy in Prostate Cancer Diagnosis: (The PRECISION Trial) demonstrated the superiority of targeted biopsy compared to systematic sampling (38% vs. 26%). It also showed that targeted biopsies decreased the detection of clinically insignificant cancer2.